Here's why Lupin is best bet to play diabetes story in India over next 2-3 yrs, says Edelweiss Securities Updated : December 20, 2019 12:35 PM IST Most of Sun Pharma's USFDA observations are procedural in nature. See approval of Ryaltris as decent opportunity for Glenmark. Published : December 20, 2019 12:35 PM IST